DPA
Evidence Fact Sheet
Docosapentaenoic Acid
DPA (docosapentaenoic acid, C22:5 n-3) is the omega-3 metabolic intermediate between EPA and DHA and a substrate for its own pro-resolving lipid mediators. No isolated-DPA human RCT exists; evidence is from biomarker pooling cohorts (CHD, type 2 diabetes, atrial fibrillation) plus preclinical/review work. Permitted as a fish-oil/seal-oil constituent (DSHEA, EFSA, ANVISA); no standalone DPA health claim.
Also known as: Docosapentaenoic acid · n-3 DPA · n-6 DPA · DPA omega-3 · Clupanodonic acid (n-3 DPA) · Osbond acid (n-6 DPA)
Overview
DPA (docosapentaenoic acid) is a long-chain omega-3 fatty acid (C22:5 n-3) that sits as the metabolic intermediate between EPA (C20:5) and DHA (C22:6) in the n-3 elongation/desaturation pathway, and serves as the substrate for a distinct family of n-3 DPA-derived specialised pro-resolving mediators (resolvins and protectins) generated independently of the EPA- and DHA-derived mediator families. It is naturally present as a minor component of fish oil and a more enriched component of seal oil (roughly 4-5% DPA by fatty-acid content), and also occurs in human breast milk. No standalone human supplementation RCT of isolated DPA exists, so there is no clinically validated DPA-specific dose; the human evidence base comes from biomarker pooling cohorts (where circulating DPA is measured) plus preclinical and review work. Regulatory status: permitted as a fish-oil/marine-oil constituent under DSHEA (US), 2002/46/EC and EFSA Reg 432/2012 (EU, where authorised omega-3 claims cover EPA and DHA), and ANVISA RDC 243/2018 (BR) — with NO standalone authorised health claim for DPA alone in any of these markets, and no independent China approval.
Mechanism of Action
Omega-3 C22:5 PUFA · sits as the metabolic intermediate between EPA (C20:5) and DHA (C22:6) in the n-3 elongation/desaturation pathway · Substrate for a distinct set of n-3 DPA-derived specialised pro-resolving mediators (resolvins and protectins) generated independently of the EPA- and DHA-derived mediator families (mechanistic / in-vitro evidence) · Modulation of inflammatory signalling including NF-kB-associated pathways in preclinical models · n-6 DPA and its 12-lipoxygenase-oxidised lipids regulate platelet reactivity in non-genomic preclinical models · Reported balancing of microglial M1/M2 polarisation in a neuronal neuroinflammation model (animal/in-vitro)
Body systems: Cardiovascular · Neurological & Cognitive · Immune System
Evidence-Based Benefits
Each benefit below is anchored to a specific PubMed-indexed study. Effect sizes, sample sizes, and p-values are reported as published; no values are inferred. Honest negatives and null results are kept alongside the positive findings, and disease-research populations are described as such — DPA is not characterized as a treatment for any disease.
Coronary Heart Disease (Circulating Biomarker)
Meta-analysis supported- RR 0.94 (0.90-0.99)total CHD · per 1-SD DPA
- RR 0.90 (0.85-0.96)fatal CHD · per 1-SD DPA
- 19 cohorts · 45,637pooled individuals
In the largest pooling project of circulating omega-3 biomarkers and coronary heart disease (19 prospective cohorts), higher blood DPA was associated with lower risk of both fatal and total CHD. Notably, DPA was the only one of the long-chain omega-3s significantly associated with total CHD in this analysis — EPA and DHA were not — which is part of the rationale for studying DPA as a distinct fatty acid rather than only as an EPA/DHA companion. This is an observational biomarker association, not a result from supplementing isolated DPA.
Reported effect: DPA per 1-SD increase: total CHD RR 0.94 (95% CI 0.90-0.99); fatal CHD RR 0.90 (95% CI 0.85-0.96); 19 cohorts, 45,637 unique individuals, 7,973 total CHD events
“Although DPA was associated with a lower risk of total CHD (RR, 0.94; 95% CI, 0.90-0.99), ALA (RR, 1.00; 95% CI, 0.95-1.05), EPA (RR, 0.94; 95% CI, 0.87-1.02), and DHA (RR, 0.95; 95% CI, 0.91-1.00) were not. ... the ω-3 biomarkers ALA, DPA, and DHA were associated with a lower risk of fatal CHD, with relative risks (RRs) of 0.91 (95% CI, 0.84-0.98) for ALA, 0.90 (95% CI, 0.85-0.96) for DPA, and 0.90 (95% CI, 0.84-0.96) for DHA.”
Source: PMID 27357102 · Del Gobbo 2016 · JAMA Intern Med
Type 2 Diabetes (Circulating Biomarker)
Meta-analysis supported- HR 0.79 (0.73-0.85)incident T2D · DPA
- 20 cohorts · 65,147pooled participants
- 16,693incident T2D cases
An individual-participant pooling project of 20 prospective cohorts found that higher circulating DPA was associated with lower incidence of type 2 diabetes, with a per-interquintile-range hazard ratio of 0.79 — numerically the strongest single-fatty-acid association among EPA, DPA and DHA in this analysis. As a biomarker study, it reflects blood DPA levels rather than an isolated-DPA supplementation trial.
Reported effect: DPA HR 0.79 (95% CI 0.73, 0.85) per interquintile range; 65,147 participants from 20 cohorts; 16,693 incident T2D cases (P < 0.001)
“per interquintile range (difference between the 90th and 10th percentiles for each fatty acid), EPA, DPA, DHA, and their sum were associated with lower T2D incidence, with hazard ratios (HRs) and 95% CIs of 0.92 (0.87, 0.96), 0.79 (0.73, 0.85), 0.82 (0.76, 0.89), and 0.81 (0.75, 0.88), respectively (all P < 0.001).”
Source: PMID 33658295 · Qian 2021 · Diabetes Care
Atrial Fibrillation (Circulating Biomarker)
Meta-analysis supported- HR 0.89 (0.83-0.95)incident AF · higher DPA
- 17 cohorts · 54,799pooled participants
- 7,720incident AF cases
A pooling project of 17 cohorts measuring omega-3 biomarkers found higher circulating DPA was associated with lower risk of incident atrial fibrillation. This contrasts with some trials of high-dose EPA-based supplements that raised AF risk, and again positions DPA's biomarker associations as distinct from supplemented EPA. It remains an observational association with measured blood DPA, not an isolated-DPA intervention.
Reported effect: DPA HR 0.89 (95% CI 0.83-0.95) for higher levels; 54,799 participants from 17 cohorts; 7,720 incident AF cases
“HRs for higher levels of DPA, DHA, and EPA+DHA, were 0.89 (95% CI: 0.83-0.95) ... Among 54,799 participants from 17 cohorts, 7,720 incident cases of AF were ascertained”
Source: PMID 37468189 · Qian 2023 · J Am Coll Cardiol
Colorectal Cancer (Circulating Biomarker)
Meta-analysis supported- RR 0.76 (0.59-0.98)colorectal cancer · DPA
- RR 0.84 (0.73-0.96)type 2 diabetes · DPA
A systematic review and meta-analysis of omega-3 PUFA biomarkers reported DPA separately for two outcomes, finding circulating DPA inversely associated with both colorectal cancer and type 2 diabetes. For cardiovascular disease and all-cause mortality this analysis pooled DPA together with EPA/DHA as 'marine-origin' omega-3s and did not report a DPA-specific estimate. These are biomarker associations, not isolated-DPA trial results.
Reported effect: DPA colorectal cancer RR 0.76 (95% CI 0.59-0.98); DPA type 2 diabetes RR 0.84 (95% CI 0.73-0.96)
“DPA (RR: 0.76, 95% CI: 0.59-0.98) ... DPA (RR: 0.84, 95% CI: 0.73-0.96)”
Source: PMID 35830775 · Jiang 2022 · Clin Nutr
Pro-Resolving Mediator Mechanism (Preclinical / Review)
Emerging / indexedReviews describe that DPA is metabolised into its own set of hydroxylated lipid mediators with anti-inflammatory and pro-resolving properties, distinct from the EPA- and DHA-derived resolvins, protectins and maresins. This is the central differentiation rationale for DPA, but the abstract is explicitly qualitative/mechanistic: it reports no quantitative human outcome and notes the mechanisms of action are not fully elucidated.
Effect size: this study reports the direction of the finding but does not state a specific numeric effect size, so none is given here rather than estimated.
“mono- di- and trihydroxy derivates of the DPAs have anti-inflammatory properties as well, even though mechanisms of their anti-inflammatory action have not been fully elucidated.”
Source: PMID 26546723 · Weylandt 2016 · Eur J Pharmacol
Dosage (research context · not a recommendation)
No standalone human supplementation RCT of DPA exists, so there is no clinically validated DPA-specific dose or intervention duration. DPA is normally ingested as a minor component of fish oil and as a more enriched component of seal oil (roughly 4-5% DPA by fatty-acid content). Where DPA appears in human studies it is as part of whole-oil EPA+DPA+DHA blends, not as an isolated compound; the existing direct-DPA evidence base is limited to reviews and preclinical (animal / in-vitro) work.
Regulatory Status · 4 Markets
- US · FDA
- Omega-3 fatty acid naturally present in fish oil and seal oil (GRAS only as a fish-oil constituent, no standalone DPA GRAS notice); permitted as a dietary supplement constituent under the DSHEA framework (omega-3 fatty acid category, structure/function claims). No DPA-specific FDA-approved health claim; DPA is not separately listed within the EPA+DHA qualified health claim framework.
- EU · EFSA
- Permitted as a food/food-supplement constituent within fish-oil / marine-oil products. EFSA Reg 432/2012 authorised omega-3 health claims cover EPA and DHA; there is NO standalone EFSA authorised health claim for DPA.
- CN · China
- No independent China regulatory status for isolated DPA; permitted only as a natural minor constituent of approved carrier oils (fish oil / seal oil). No standalone novel-food or health-food approval for DPA alone.
- BR · ANVISA
- Permitted as a constituent of food supplements (RDC 243/2018) when present via fish oil or seal oil. IN 28/2018 Anexo V alegação funcional covers EPA and DHA ("Os ácidos graxos ômega 3 EPA e DHA auxiliam na redução dos triglicerídeos."); there is no separate ANVISA functional claim for DPA alone.
Safety
No DPA-specific human safety dataset exists; tolerability is expected to parallel other long-chain omega-3 fatty acids, i.e. mild gastrointestinal upset typical of fish-oil-class products. As with all omega-3 PUFAs, high intakes may modestly affect platelet function and bleeding tendency, which is relevant for anticoagulant/antiplatelet users and the perioperative window. DPA is naturally present in fish oil, seal oil and human breast milk. Not intended to diagnose, treat, cure or prevent any disease; speak with a qualified healthcare professional before use, especially if pregnant, nursing, on medication, or managing a medical condition.
Related
Goals: heart-health
Lifestyles: senior-60-plus
References
PubMed-indexed citations anchoring the benefit findings above. Effect sizes are reported as published.
- PMID 27357102 · Del Gobbo 2016 · JAMA Intern Med — Coronary Heart Disease (Circulating Biomarker)
- PMID 33658295 · Qian 2021 · Diabetes Care — Type 2 Diabetes (Circulating Biomarker)
- PMID 37468189 · Qian 2023 · J Am Coll Cardiol — Atrial Fibrillation (Circulating Biomarker)
- PMID 35830775 · Jiang 2022 · Clin Nutr — Colorectal Cancer (Circulating Biomarker)
- PMID 26546723 · Weylandt 2016 · Eur J Pharmacol — Pro-Resolving Mediator Mechanism (Preclinical / Review)
Frequently Asked Questions
1. Is there a human clinical trial of DPA on its own?
No. As of this review, no randomized controlled trial has tested isolated/purified DPA supplementation in humans. DPA is normally consumed as a minor component of fish oil or a more enriched component of seal oil, and where it appears in human data it is either part of whole-oil EPA+DPA+DHA blends or measured as a circulating biomarker. The strongest human evidence — for coronary heart disease, type 2 diabetes and atrial fibrillation — comes from observational pooling projects of blood omega-3 biomarkers, not from supplementing DPA alone.
2. What does the biomarker evidence actually show for DPA?
In large pooling projects, higher circulating DPA has been associated with lower risk of several outcomes: total coronary heart disease (RR 0.94 per 1-SD), incident type 2 diabetes (HR 0.79 per interquintile range), incident atrial fibrillation (HR 0.89), and colorectal cancer (RR 0.76). These are associations from people's measured blood DPA levels in observational cohorts — they show a consistent direction but cannot establish that taking DPA causes these effects, since no isolated-DPA intervention has been run.
3. Why is DPA studied separately from EPA and DHA?
DPA sits as the metabolic intermediate between EPA and DHA and is the substrate for its own family of pro-resolving lipid mediators generated independently of the EPA- and DHA-derived families. In the 19-cohort coronary heart disease pooling project, DPA was actually the only long-chain omega-3 significantly associated with lower total CHD risk, while EPA and DHA were not — which is the kind of finding that motivates treating DPA as a distinct fatty acid. The mediator mechanism itself, however, is supported only by preclinical and review-level work that reports no human effect size.
4. Are there safety or regulatory considerations specific to DPA?
There is no DPA-specific human safety dataset; tolerability is expected to parallel other long-chain omega-3 fatty acids (mild GI upset typical of fish-oil-class products), and like all omega-3 PUFAs high intakes may modestly affect platelet function — relevant for anticoagulant/antiplatelet users and the perioperative window. Regulatory-wise, DPA is permitted only as a fish-oil/marine-oil constituent (DSHEA in the US, 2002/46/EC in the EU, ANVISA RDC 243/2018 in Brazil), and there is no standalone authorised health claim for DPA alone in any of these markets and no independent China approval. This page reports research findings and is not medical or dosing guidance.
Last evidence review: 2026-06-13